News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SK Bio-Pharmaceuticals Announces a Strategic Alliance for Innovative Drug Development With Chinese Biopharmaceutical Companies



3/28/2013 9:59:05 AM

SEOUL, South Korea--(BUSINESS WIRE)--The South Korean pharmaceutical company, SK Biopharmaceuticals, announced that they entered into a collaboration agreement with PKU International HealthCare Group, China, and Shanghai Medicilon, China, for its novel new small molecule SKL-PSY that is being developed for the treatment of depression and bipolar disorder. SK Biopharmaceuticals and Shanghai Medicilon have been conducting various preclinical experiments for SKL-PSY since 2011. When its preclinical development has been successfully completed through the efforts of Medicilon CRO services, they will start clinical development with the newly-joined partners, Southwest Synthetic Pharmaceuticals and PKUCare Pharmaceutical R&D Center, both of which are subsidiaries of PKU International HealthCare Group.

Read at BioSpace.com
Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES